WO2024161311 - TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION
National phase entry is expected:
Publication Number
WO/2024/161311
Publication Date
08.08.2024
International Application No.
PCT/IB2024/050860
International Filing Date
30.01.2024
Title **
[English]
TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION
[French]
TRAITEMENT DE L'INSUFFISANCE OU DU DYSFONCTIONNEMENT DES CELLULES BÊTA
Applicants **
NOVMETAPHARMA CO., LTD.
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors
KIM, Hail
JUNG, Hoeyune
KIM, Kyun Hoo
LEE, Joonyub
LEE, Hyeonkyu
LEE, Heon Jong
Priority Data
63/482,357
31.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2651 | |
| EPO | Filing, Examination, Granting | 15307 | |
| Japan | Filing, Examination, Granting | 2308 | |
| South Korea | Filing, Examination, Granting | 1802 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
27,408
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A method and composition for treating and/or preventing β-cell dysfunction and/or protecting impaired β-cells are disclosed. The method includes administering an effective amount of cyclo (his-pro) (CHP), alone or with zinc, to a subject. The composition contains an effective amount of cyclo (his-pro) (CHP) as an active ingredient. The composition may further contain zinc and/or other antidiabetic agent, or can be administered in combination with zinc and/or other antidiabetic agent.[French]
L'invention concerne une méthode et une composition pour traiter et/ou prévenir un dysfonctionnement des cellules β et/ou protéger des cellules β altérées. La méthode comprend l'administration à un sujet d'une quantité efficace de cyclo(his-pro) (CHP), seule ou avec du zinc. La composition contient une quantité efficace de cyclo(his-pro) (CHP) en tant que principe actif. La composition peut contenir en outre du zinc et/ou un autre agent antidiabétique, ou peut être administrée en association avec du zinc et/ou un autre agent antidiabétique.